You have 9 free searches left this month | for more free features.

Chemoradiation Therapy

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neoadjuvant Chemoradiation Therapy, Rectal Cancer, Immunotherapy Trial in Shanghai (xintilimab injection, Control)

Recruiting
  • Neoadjuvant Chemoradiation Therapy
  • +3 more
  • xintilimab injection
  • Control
  • Shanghai, Shanghai, China
    Department of Colorectal Surgery in Changhai Hospital
Aug 5, 2022

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2022

Lung Cancer Stage III Trial in New Brunswick (AN0025)

Not yet recruiting
  • Lung Cancer Stage III
  • Atlanta, Georgia
  • +1 more
Nov 2, 2022

Tumors, Esophageal Tumors, Esophagus Tumor Trial run by the National Cancer Institute (NCI) (Nivolumab, Entinostat, Montanide(R)

Not yet recruiting
  • Neoplasms
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 16, 2023

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated

Enrolling by invitation
  • Cardiotoxicity
  • +3 more
  • Chemoradiation
  • Birmingham, Alabama
  • +6 more
Nov 1, 2022

Cervical Cancer Trial in Chongqing (salvage surgery)

Recruiting
  • Cervical Cancer
  • salvage surgery
  • Chongqing, Chongqing, China
    Chongqing Cancer Hospital
Feb 20, 2023

Rectal Cancer Trial in Taipei (Surgery)

Recruiting
  • Rectal Cancer
  • Surgery
  • Taipei, Taiwan
    Jin-Tung LIANG
Jul 27, 2023

Oropharyngeal Squamous Cell Carcinoma Trial in Saint Louis (CUE-101)

Recruiting
  • Oropharyngeal Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 22, 2022

Stage III Non-small-cell Lung Cancer Trial in Foshan, Guangzhou (other, radiation, drug)

Recruiting
  • Stage III Non-small-cell Lung Cancer
  • Neoadjuvant therapy
  • +4 more
  • Foshan, Guangdong, China
  • +2 more
Oct 25, 2022

Gastric Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Houston (Aerobic Exercise, Dietary Intervention, Nutritional

Withdrawn
  • Gastric Adenocarcinoma
  • Pancreatic Adenocarcinoma
  • Aerobic Exercise
  • +5 more
  • (no location specified)
Oct 26, 2022

Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)

Recruiting
  • Stage III Non-small Cell Lung Cancer
  • Neoadjuvant chemo-immunotherapy
  • +5 more
  • Guangzhou, China
    Sun Yat-sen University
Jul 19, 2022

Cervical Cancer Trial in Chengdu (NACT, CCRT, Brachytherapy)

Not yet recruiting
  • Cervical Cancer
  • Chengdu, Sichuan, China
    Sicchuan cancer hospital
Dec 28, 2021

NSCLC, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation Trial in Beijing (Tislelizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Peking University Cancer Hospital and Institute
Mar 4, 2023

NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

Recruiting
  • Non-small Cell Lung Cancer Stage III
  • +2 more
  • Busan, Korea, Republic of
  • +12 more
Jan 17, 2023

Lung Cancer Trial in Palo Alto (Hypofractionated accelerated radiation therapy)

Not yet recruiting
  • Lung Cancer
  • Hypofractionated accelerated radiation therapy
  • Palo Alto, California
    Stanford University
Oct 11, 2023

Cervical Cancer, Stage IIB Trial in Mexico City (Placebo dairy beverage)

Completed
  • Cervical Cancer, Stage IIB
  • Placebo dairy beverage
  • Mexico City, Tlalpan, Mexico
    National Cancer Institute of Mexico
Feb 16, 2023

Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +2 more
  • RP3
  • +3 more
  • (no location specified)
Feb 21, 2023

Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Tumor in the Spine Trial in Houston (Computed Tomography,

Recruiting
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Malignant Neoplasm in the Spine
  • Computed Tomography
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 13, 2022

Uterine Cervical Tumors, Sintilimab Trial in Xuzhou (Sintilimab, Cisplatin, External Beam Radiotherapy (EBRT))

Recruiting
  • Uterine Cervical Neoplasms
  • Sintilimab
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 24, 2021

NSCLC Trial in Jinan (TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation, TQB2450 injection, sequential

Not yet recruiting
  • Non-small Cell Lung Cancer
  • TQB3728 tablets, TQB2450 injection, sequential or concurrent chemoradiation
  • TQB2450 injection, sequential or concurrent chemoradiation
  • Jinan, Shandong, China
    Cancer Hospital Affiliated to Shandong First Medical University
May 5, 2023

Locally Advanced Head and Neck Carcinoma Trial in Los Angeles (Dietary Supplement, Quality-of-Life Assessment, Questionnaire

Recruiting
  • Locally Advanced Head and Neck Carcinoma
  • Dietary Supplement
  • +2 more
  • Los Angeles, California
    University of California at Los Angeles
Mar 23, 2022

Oral Mucositis Trial (RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2)

Not yet recruiting
  • Oral Mucositis
  • (no location specified)
Jul 31, 2023

Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX Trial in Kaunas (Radiotherapy 50 Gy, Fluorouracil/folic acid,

Recruiting
  • Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX
  • Radiotherapy 50 Gy
  • +2 more
  • Kaunas, Lithuania
    Rita Ambraziene
May 12, 2022

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (drug, radiation, procedure)

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 25, 2022

Locally Advanced NSCLC Trial in Beijing (Camrelizumab, PD-1 mAb, Apatinib, VEGFR2 antibody)

Recruiting
  • Locally Advanced Non-Small Cell Lung Cancer
  • Camrelizumab, PD-1 monoclonal antibody
  • Apatinib, VEGFR2 antibody
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Aug 15, 2022